U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06987383) titled 'Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity' on May 15.
Brief Summary: This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: Vibegron
A drug in a class of medications called beta-3 adrenergic agonists; approved for use with Overactive Bladder; 75mg tablets will be used in this study
...